Use of calcium antagonists in patients with ischemic heart disease and systemic hypertension

American Journal of Cardiology

Volumn 79, Issue 10 A, 1997, Pages 33-38

  Frishman, William H ^a   Michaelson, M Dror ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ANTAGONIST;

ANTIHYPERTENSIVE THERAPY; CONFERENCE PAPER; DRUG EFFECT; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CONTROLLED CLINICAL TRIALS; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA;

EID: 0030842083     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00270-1     Document Type: Conference Paper

References (36)

1. Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol. 38:1976;786-800.
2. Frishman WH. The interplay of ischemic and hypertensive pathophysiology on cardiac function. J Cardiovasc Pharm. 18:((suppl 4)):1991;S17-S21.
3. O'Rourke RA. Rationale for calcium entry blocking drugs in systemic hypertension complicated by coronary artery disease. Am J Cardiol. 56:1985;H34-H40.
4. Kannel WB, Gordon T, Offut D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study. Ann Intern Med. 71:1969;89-105.
5. Kannel WB, Doyle JT, McNamara PM, Quickenton P, Gordon T. Precursors of sudden death: factors related to the incidence of sudden death. Circulation. 51:1975;606-613.
6. Packer M, Frishman WH. Calcium Channel Antagonists in Cardiovascular Disease. 1984;Appleton-Century Crofts, Norwalk, CT.
7. Weiner DA. Calcium channel blockers. Med Clin North Am. 72:1988;83-115.
8. Lazar EJ, Frishman WH, Grover N. Medical therapy of the hypertensive patient with concomitant angina pectoris. Cardiol Clinics. 9:1991;167-176.
9. Little WC, Cheng CP, Elvelin L, Nordlander M. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 9:1995;657-663.
10. Frishman WH, Charlap S, Kimmel B, Goldberger J, Phillippides G, Klein N. Calcium-channel blockers for combined angina pectoris and systemic hypertension. Am J Cardiol. 57:1986;22D-29D.
11. Lewis BS. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. Am J Cardiol. 75:1995;46E-53E.
12. Glasser SP. Nisoldipine coat core as concomitant therapy in chronic stable angina pectoris. Am J Cardiol. 75:1995;65E-70E.
13. Rousseau MF, Melin J, Benedict CR, Ahn S, Raphael D, Bornemann M, Pouler H. Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction. Eur Heart J. 15:1994;957-964.
14. Frishman WH, Klein NA, Strom JA, Wilens H, LeJemtel TH, Jentzer J, Siegel L, Klein P, Kirschen N, Silverman R, Pollack S, Doyle R, Kirsten E, Sonnenblick EH. Superiority of verapamil to propranolol in stable angina pectoris: a double-blind, randomized crossover trial. Circulation. 65:1982;I51-I59.
15. Frishman WH, Klein NA, Klein P, Strom JA, Tawil R, Strair R, Wong B, Roth S, LeJemtel TH, Pollack S, Sonnenblick EH. Comparison of oral propanolol and verapamil for combined systemic hypertension and angina pectoris. Am J Cardiol. 50:1982;1162-1772.
16. Frishman WH, Charlap S, Goldberger J, Kimmel B, Stroh J, Dorsa F, Allen L, Strom J. Comparison of diltiazem and nifedipine for both angina pectoris and systemic hypertension. Am J Cardiol. 56:1985;H41-H46.
17. Kawanishi DT, Leman RB, Pratt CM, O'Rourke RA. Efficacy and safety of sustained-release diltiazem as replacement therapy for β blockers and diuretics for stable angina pectoris and coexisting essential hypertension. Am J Cardiol. 60:1987;291-351.
18. Klein MD, Weiner DA. Treatment of angina pectoris and hypertension with sustained-release calcium channel blocking drugs. Circulation. 75:((suppl V)):1987;V110-V113.
19. Frishman WH, Charlap S. Calcium-channel blockers for combined systemic hypertension and myocardial ischemia. Circulation. 75:((suppl V)):1987;V154-V162.
20. Frishman WH, Lazar EJ. Calcium channel blockers in patients with both hypertension and angina pectoris. J Cardiovasc Pharm. 12:((suppl 6)):1988;S69-S74.
21. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghanathan TE, Weiss NS, Rosedaal FR, Lemaitre RN, Smith NL, Wahl PW, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive therapies. JAMA. 274:1995;620-625.
22. Furberg CD, Psaty BM, Meyers JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 92:1995;1326-1331.
23. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? Arch Intern Med. 155:1995;2157-2161.
24. 2+ antagonists in hypertensive patients in the absence and presence of β -adrenergic blockade. Am Heart J. 96:1978;218-226.
25. Husted SE, Nielson HK, Christensen CK, Lederballe Pedersen O. Long-term therapy of arterial hypertension with nifedipine given alone or in combination with β -adrenoceptor blocking agents. Eur J Pharmacol. 22:1982;101-103.
26. Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA. 275:1996;423-424.
27. Braun S, Boyko V, Behar S, Reicher-Reiss H, Shotan A, Schlesinger Z, Rosenfeld T, Palant A, Friedensohn A, Laniado S, Goldbourt U. Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol. 28:1996;7-11.
28. Mehta JL, Subramanian VB. Calcium blockers and risk of myocardial infarction and coronary heart disease mortality. Circulation. 93:1996;1472-1476.
29. Fagan TC. Calcium antagonists and mortality. Another case of the need for clinical judgement (editorial). Arch Intern Med. 155:1995;2145-2161.
30. Borhani NO, Nercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, Kappagoda T, Rocco MV, Schnaper HW, Sowers JR, Bond G. Final outcome results of the Multicentre Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA. 276:1996;785-791.
31. Chobanian AV. Calcium channel blockers: lessons learned from MIDAS and other clinical trials. JAMA. 276:1996;829-830.
32. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med. 155:1995;2150-2156.
33. Burt VL, Whelton P, Roccella EJ. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 25:1995;305-313.
34. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med. 335:1996;1107-1114.
35. Poole-Wilson PA. Improved diastolic function with the calcium antagonist nisoldipine (coat core) in patients with post-myocardial infarction: results of the DEFIANT study. Eur Heart J. 13:1992;1496-1505.
36. Poole-Wilson PA. Doppler flow and echocardiography in functional cardiac insufficiency: assessment of nisoldipine therapy. Eur Heart J. 18:1997;31-40.